EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Cytokines as Biomarkers of Treatment Response to IFN β in Relapsing-Remitting Multiple Sclerosis

Nikolaos Dimisianos, Maria Rodi, Dimitra Kalavrizioti, Vasileios Georgiou, Panagiotis Papathanasopoulos, Athanasia Mouzaki

Multiple Sclerosis International · 2014 · 2014 · 1-8

DOI: 10.1155/2014/436764 ↗
AbstractBibliografische Angaben

Abstract

Background . MS patients show a remarkable heterogeneity in their response to disease modifying treatments. Given the need for early treatment initiation and the diversity of available options, a predictive marker that indicates good or poor response to treatment is highly desirable. Objective . To find a biomarker for treatment response to IFN β among pro- and anti-inflammatory cytokines. Materials and Methods . IFN- γ , TNF- α , IL-2, IL-4, IL-6, IL-10, IL-17A, and TGF- β 1 levels were measured in serum and CSF of 43 patients with RR-MS who were followed up for a mean period of 5.3 years. Thirty-five patients received IFN β treatment and were divided into good responders (GR, n = 19) and poor responders (PR, n = 16). The remaining 8 patients showed a very favorable outcome and remained untreated (noRx). Results . GR had significantly higher serum baseline levels of IL-17A than PR and significantly higher serum levels of IL-17A, IFN- γ , TNF- α , and IL-2 than noRx. PR had significantly higher IFN- γ serum levels than noRx. No significant differences were observed in serum levels of IL-6, IL-4, IL-10, and TGF- β 1 or the levels of all cytokines measured in CSF between the 3 groups of patients. Conclusions . Baseline serum levels of IL-17A can be used as a biomarker of IFN β treatment response.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →